arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Axogen, Inc.

AXGN
$48.71 ▼ -2.62 (-5.09%) at close
Healthcare ·Electromedical & Electrotherapeutic Apparatus ·USElectromedical & Electrotherapeutic Apparatus
67 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
33
Health
Poor
Bearish
auto_awesome

Analytical Summary

Axogen, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.7B
Dividend Yield —
Revenue Growth 26.2% ↗
Op. Margin 1.3% ↗
ROIC 0.2% ↗
FCF / Share $0.27 ↗
Trailing P/E 1217.8x
Price / Book 5.9x
FCF Yield 0.6%
Debt / Equity 0.00
info Valuation on last close. End-of-day price, Nov 5, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$75.83M
↑ +26.2% —
Net Income Profit after all expenses
$2.33M
↑ +229.7% —
Operating Margin Operating profit as % of sales
1.3%
↑ +140.7% 22th
FCF / Share Free cash flow per share
$0.27
↑ +131.4% —
Long-Term Debt Long-term obligations
$0.00
— —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
21
Returns ↑
33
Financial Health →
51
Cash Quality ↓
29

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 17 years · 67 quarters